Hepion Pharmaceuticals (HEPA) Stock Price, News & Analysis

Company Overview

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Key Stats

• Today's Range: $0.70 to $0.70
• 50-Day Range: $0.57 to $0.82
• 52-Week Range: $0.55 to $4.47
• Volume: 6,857 shs
• Average Volume: 84,614 shs
• Market Capitalization: $4.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

HEPA Stock Analysis - Frequently Asked Questions

How have HEPA shares performed this year?

Hepion Pharmaceuticals' stock was trading at $3.24 at the beginning of 2024. Since then, HEPA shares have decreased by 78.7% and is now trading at $0.69.
View the best growth stocks for 2024 here.

How were Hepion Pharmaceuticals' earnings last quarter?

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) posted its earnings results on Sunday, November, 15th. The company reported ($13.80) EPS for the quarter, missing the consensus estimate of ($10.20) by $3.60.

When did Hepion Pharmaceuticals' stock split?

Hepion Pharmaceuticals's stock reverse split on Thursday, May 11th 2023. The 1-20 reverse split was announced on Thursday, May 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Hepion Pharmaceuticals' major shareholders?

Top institutional investors of Hepion Pharmaceuticals include Anson Funds Management LP (3.33%). Insiders that own company stock include Robert T Foster and Peter Wijngaard.
View institutional ownership trends.

How do I buy shares of Hepion Pharmaceuticals?

Shares of HEPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Hepion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hepion Pharmaceuticals investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), FuelCell Energy (FCEL), NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), Advanced Micro Devices (AMD) and Meta Platforms (META).

Company Calendar

• Last Earnings: 11/15/2020
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HEPA
• CUSIP: N/A
• CIK: 1583771
• Web: www.hepionpharma.com
• Phone: (732) 902-4000
• Fax: 732-902-4100
• Employees: 20
• Year Founded: 2013

Profitability

• EPS (Most Recent Fiscal Year): ($4.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-48,930,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -812.56%
• Return on Assets: -207.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.30
• Quick Ratio: 1.30

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.30) per share
• Price / Book: -2.30

Miscellaneous

• Outstanding Shares: 6,960,000
• Free Float: 6,822,000
• Market Cap: $4.80 million
• Optionable: No Data
• Beta: 1.81